Autopsy report · NCT02766140

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

“difficulty in recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 months before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Sponsor type

Industry

Conditions

Non Squamous Non Small Cell Lung

Interventions

SHR1020 plus Docetaxel; Placebo plus Docetaxel

Participants

12

Sites

1

Countries

China

Trials that died the same way

• Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.
  “Difficulties in recruitment” (98% match in meaning)
• Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen
  “Difficulty with recruitment.” (97% match in meaning)
• The Occlusive Dressing
  “recruitment difficulty” (97% match in meaning)
• Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain
  “difficulty of recruitment” (97% match in meaning)
• Morphine in Moderate Obstructive Sleep Apnoea
  “Difficulties with recruitment” (97% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.